about
Altered folding, turnover, and polarized sorting act in concert to define a novel pathomechanism of congenital sucrase-isomaltase deficiencyCompound heterozygous mutations affect protein folding and function in patients with congenital sucrase-isomaltase deficiencyImpaired trafficking and subcellular localization of a mutant lactase associated with congenital lactase deficiency.Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies.The Organic Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane of the Human Jejunum and Caco-2 Monolayers.Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals.The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.Expression, regulation and function of intestinal drug transporters: an update.OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide.Effects of frequently used pharmaceutical excipients on the organic cation transporters 1-3 and peptide transporters 1/2 stably expressed in MDCKII cells.Steroid hormones specifically modify the activity of organic anion transporting polypeptides.Pharmaceutical excipients influence the function of human uptake transporting proteins.A LC-MS/MS method to evaluate the hepatic uptake of the liver-specific magnetic resonance imaging contrast agent gadoxetate (Gd-EOB-DTPA) in vitro and in humans.Expression of Organic Anion Transporting Polypeptide 1A2 in Red Blood Cells and Its Potential Impact on Antimalarial Therapy.Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers.Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters.Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.Affinity of Ketamine to Clinically Relevant Transporters.Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals.Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imagingCharacterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acidA modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IVCongenital and putatively acquired forms of sucrase-isomaltase deficiency in infancy: effects of sacrosidase therapyResponse
P50
Q28302518-DA890AFC-268A-4622-A44D-B312185D486BQ28305699-0803E357-1485-44BB-B5F4-8F452C397356Q34604459-25A9F13B-A012-43EA-931D-7653AD8D3973Q35135974-B26EFDE8-C02E-45E4-BDE3-1A7ACE8A11C7Q38705793-87E5E87A-5A43-476C-BE4A-763BCD302C79Q38707799-58E40BC6-9A78-4389-A292-EBF3426A0B29Q38773623-C85847F4-B031-4A96-BDC7-729DA149A2C7Q38928248-A3CAA39A-FFA5-41DF-9F93-77C16A6BCDCCQ38950177-A9A65AEC-6AFE-4347-B89B-1CD0DBF5ABD0Q39073271-4FDE7613-9380-4B33-9A71-1CA65A94923DQ39141816-1BB327E8-65EA-4500-9557-031CC72DE696Q39277909-8A94278E-D52A-41E9-A9EB-B3FFC30CE099Q39312505-4A32AC4D-256F-4F1B-92D3-95A156505A9EQ39385276-1CDF1661-73FF-4BDB-99C4-9544FE1A34A0Q39509379-274CC3D5-9483-48CB-85E9-85C4D8B6E22CQ39582716-9E25CD54-2EB8-4C35-A7DC-52BDBE8CD588Q39712719-3D408CD4-E7F9-4F24-BDA3-F3719C779841Q42703302-086166E6-943D-4A56-83A1-25A5F3FB45DAQ47346035-A2E826D5-BDA2-415E-9F3F-F0F0C90FAC9EQ52857281-348321AC-1D84-4E48-9B46-F5AABAEC2E46Q56774128-9F763BA8-5F95-4D5E-AF47-21236FEB3639Q57154102-21739334-6AAD-4B7C-8BBE-2E3E11EE41C9Q84286537-796377AB-C68F-45F9-99A4-1710A10F6B97Q84401216-BD4A7BD4-7C03-460F-8620-50EFD6A855FAQ95825657-C20956A8-0C2B-4785-BB77-9743868DBB4C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Markus Keiser
@ast
Markus Keiser
@en
Markus Keiser
@es
Markus Keiser
@nl
Markus Keiser
@sl
type
label
Markus Keiser
@ast
Markus Keiser
@en
Markus Keiser
@es
Markus Keiser
@nl
Markus Keiser
@sl
prefLabel
Markus Keiser
@ast
Markus Keiser
@en
Markus Keiser
@es
Markus Keiser
@nl
Markus Keiser
@sl
P106
P1153
14007487900
P31
P496
0000-0003-4842-6273